ESC 2018

ESC 2018 | MARINER: Rivaroxaban as Thromboprophylaxis after Hospitalization

For acute patients hospitalized for a clinical disease (e.g.: heart failure), indicating rivaroxaban for 6.5 weeks after...

ESC 2018 | FUTURE: A Thorn in FFR and More Questions than Answers

As observed at the preliminary analysis that motivated the FUTURE trial early termination, the use of fractional...

ESC 2018 | FRANCE-TAVI: Atrial Fibrillation and Anticoagulation Associated to Mortality in TAVR

Some of the many ongoing randomized studies including patients with atrial fibrillation (AF) might finally answer the...

ESC 2018

Here you will find the highlights of the ESC 2018, held on August 25-29 in the city...